Assembly Biosciences, Inc., a biopharmaceutical company, develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus (HBV) and C. difficile-associated infections (CDAD). It is involved in developing core protein allosteric modulators that modulate the HBV core protein, a polyfunctional viral protein, at various complementary points in the viral lifecycle; and microbiome program, a treatment for CDAD, for targeted delivery of complex agents to select regions of the gastrointestinal tract. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in New York, New York.

Sector & Industry Watch List